Audentes Therapeutics (BOLD): Initiating Coverage with an Outperform Rating - Piper Jaffray

Piper Jaffray analyst, Joshua Schimmer, initiated coverage on Audentes Therapeutics (NASDAQ: BOLD) with an Overweight rating price target of $24.

The company is capitalizing on recent wins in the gene therapy field and is
charting its own path with a differentiated strategy, focusing on orphan and ultra-orphan
diseases with a high unmet need which is uniquely suited to gene therapy. BOLD's lead
program targets X-linked myotubular myopathy (XLMTM), with robust preclinical data
indicating long-term durable correction of the phenotype with clinical data next year.
Behind XLMTM, the company has attractive programs with promising preclinical data
for Crigler-Najjar, Pompe, and Catecholaminergic polymorphic ventricular tachycardia
(CPVT). As such, we see BOLD as well-positioned in the rapidly evolving gene therapy
landscape.

The $24 PT is based on a based on a DCF analysis through 2024E.

For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.

Shares of Audentes Therapeutics closed at $14.70 yesterday.

You May Also Be Interested In

• Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
• UBS Downgrades SSP Group Plc. (SSPG:LN) (SSPPF) to Neutral
• ConocoPhillips (COP) PT Raised to $157 at Piper Sandler